Stock screener

BTAI

Conviction 14HealthcareScan · Thu, Jun 25, 2026
BTAI$1.25-4.58%
ResistanceSupportVol 14Insider sell
63 bars
4
Vol MA14 640.99K
Mar 26Apr 14May 1May 19Jun 8Jun 25
BioXcel Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.bioxceltherapeutics.com
Price1.25
Change-4.58%
Gap+1.53%
Rel volume0.31×
Avg volume683.76K
Avg $ vol811.72K
SMA 201.18
SMA 501.17
SMA 2001.74
Price vs 50+6.76%
Price vs 200-28.20%
MA stackmixed
50/200 cross
Supertrendup · 1.07
RSI (14)55
MACD hist0.02
MACD crossbull · 6d
Stoch %K / %D65 / 75
ADX (14)30
+DI / −DI33 / 13
RSI divergenceBullish
MACD divergence
ATR %+6.67%
ADR %6.87%
52w high6.80
52w low1.02
From 52w high-81.62%
Above 52w low+22.55%
New 52w highNo
SqueezeOff
Bollinger width22.78%
%B0.74
Donchian pos63.49%
Donchian high1.37
Donchian low1.05
AVWAP (52w high)3.54
vs AVWAP high-64.73%
AVWAP (52w low)1.17
vs AVWAP low+6.43%
OBV trendFlat
Chaikin MF (20)-0.30
Today vs 20d0.31×
Avg vol (14d)640.99K
Avg vol (20d)683.76K
Avg $ vol (20d)811.72K
Market cap38.6M
RS 3m (vs SPY)-20.65%
RS 6m (vs SPY)-32.01%
RS line new highNo
Trend template1/8
Technical rank28.6
1 week+5.04%
1 month+2.46%
3 months-12.59%
6 months-28.16%
1 year-27.75%
YTD-26.47%
P/E-0.55
P/B-0.37
P/S60.12
P/FCF-0.67
EPS-5.73
Div yield
ROE66.23%
ROA-205.43%
Debt/Eq-0.95
Current0.62
EV/EBITDA-2.43
Gross margin
Net margin
Rev growth-71.67%
EPS growth-17.28%
Price target
Target upside
Analyst rating
Institutional
Ent. value121.71M
Revenue206K
Net income-12.69M
Gross profit
Free cash flow-57.62M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out30.88M
Employees29
ListedThu, Mar 8, 2018
Free float26.13M
Float %96.5%
Short interest3.53M
Days to cover4.5d
Short volume30.8%
Squeeze score49 / 100
Next earnings
EPS forecast
Last EPS vs est
Last surprise
Setup gradeD
Conviction14 / 100
Pattern quality
Tech rank28.6 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance1.39
Support1.06
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BTAI

All disclosures →
No recent disclosed trades by Congress in BTAI. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BTAI · 4 buys · 6 sells

InsiderSideShares
Yocca Frank
Chief Scientific Officer · Restricted Stock Units · 2026-06-15
Exercise35
Rodriguez Javier
See Remarks · Common Stock · 2026-06-15
Exercise35
Mehta Vimal
CEO and President · Common Stock · 2026-06-15
Exercise219
Yocca Frank
Chief Scientific Officer · Common Stock · 2026-06-15
Exercise35
Steinhart Richard I
Chief Financial Officer · Common Stock · 2026-06-15
Exercise35
Steinhart Richard I
Chief Financial Officer · Restricted Stock Units · 2026-06-15
Exercise35
Mehta Vimal
CEO and President · Restricted Stock Units · 2026-06-15
Exercise219
Rodriguez Javier
See Remarks · Restricted Stock Units · 2026-06-15
Exercise35
Yocca Frank
Chief Scientific Officer · Common Stock · 2026-05-20
Sell6.84K
Mehta Vimal
CEO and President · Common Stock · 2026-05-20
Sell19.42K

SEC filings

EDGAR filings in BTAI

EDGAR →

No recent SEC filings on file for BTAI.

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.